
|Videos|April 17, 2022
Dr. Talley on “landmark study” of investigational oral treatment for complicated UTIs
Author(s)Urology Times staff
“If approved, tebipenem could provide a new oral treatment option for patients with cUTI who have limited or no alternative oral options," says Angela Talley, MD.
Advertisement
In this video, Angela Talley, MD, discusses next steps and the take-home message for the recent New England Journal of Medicine paper, “Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,” for which she served as senior author. Talley is senior vice president of Clinical Development at Spero Therapeutics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Experts discuss the challenge of detecting CIS in bladder cancer
2
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
3
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
4
First-in-human bladder transplant demonstrates sustained function at 6 months
5











